Temasek Leads Series B Round in Hangzhou Just Biotherapeutics
Posted on 08/09/2017
Institutional investors are taking a deeper look into China’s healthcare sector, especially in the area of biotherapeutics. Singapore’s Temasek Holdings led a Series B round in Hangzhou Just Biotherapeutics, Ltd. (Just China), a company focused on developing global antibody and recombinant protein bio-therapeutics. Other investors in the round include Lilly Asia Ventures and ARCH Venture […]
- Alternatives
- Asia
- Bank of China
- China
- Hangzhou Economic & Technological Development Area
- Hangzhou Just Biotherapeutics
- Singapore
- Taikang
- Temasek Holdings
- Venture Capital
